NRSN

Neurosense Therapeutics Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website neurosense-tx.com
Employees(FY) 14
ISIN IL0011809592

Performance

-8.89%

1W

-27.65%

1M

-3.91%

3M

+105.34%

6M

+56.69%

YTD

-28.9%

1Y

Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Advanced Technical Analysis

Technical Analysis of NRSN 2024-05-03

Overview:

In analyzing the technical indicators for NRSN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...

See more ...

Recent News & Updates

2024-05-06 20:45
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients(Prnewswire)
2024-05-01 21:19
NeuroSense Announces First Quarter 2024 Business Update(Prnewswire)
2024-04-21 20:30
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease(Prnewswire)
2024-04-17 20:30
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting(Prnewswire)
2024-04-11 20:30
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024(Prnewswire)
2024-04-10 07:16
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement(Prnewswire)
2024-04-08 20:30
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics(Prnewswire)
2024-04-05 08:52
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-04 21:29
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update(Prnewswire)
2024-02-20 19:30
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial(Prnewswire)
2024-02-06 20:27
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule(Prnewswire)
2024-01-29 19:30
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024(Accesswire)
2024-01-08 19:45
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts(Prnewswire)
2023-12-27 04:00
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement(Prnewswire)
2023-12-13 20:24
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial(Prnewswire)
2023-12-04 19:00
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints(Prnewswire)
2023-12-04 03:01
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023(Prnewswire)
2023-11-27 19:45
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update(Prnewswire)
2023-11-12 20:20
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness(Prnewswire)
2023-11-08 20:00
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences(Prnewswire)
2023-11-05 19:30
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023(Prnewswire)
2023-10-31 21:00
NeuroSense Therapeutics to Participate in BIO-Europe Fall(Prnewswire)
2023-10-18 22:30
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics Lead Drug Candidate, PrimeC(Accesswire)
2023-10-16 20:30
NeuroSense CEO Provides Q3 2023 Update(Prnewswire)
2023-10-03 21:10
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model(Prnewswire)
2023-10-03 19:00
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now(Globenewswire)
2023-10-02 19:00
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now(Globenewswire)
2023-10-01 20:46
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results(Prnewswire)
2023-09-19 21:05
European Medicines Agency Grants NeuroSense SME Status(Yahoo Finance)
2023-09-18 21:00
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC(Yahoo Finance)

Page 1 of 4

previousnext